A study published recently has established the feasibility of systemic oncolytic virotherapy as a potential treatment for myeloma patients. Designed as a proof of concept, the study, published in the Mayo Clinic Proceedings, found that two relapsed and refractory myeloma patients who received high doses of an engineered measles virus achieved significant responses as demonstrated by paraprotein reduction and resolution of tumour mass. A Phase II trial involving more patients is planned.

Read the full article ยป